Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845

• Drug: PF 03882845 and Placebo
  
  The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
• Drug: PF 03882845 and Placebo
  
  The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.

• Placebo Comparator: Cohort 1
  
  Cohort 1 completed.
  Intervention: Drug: PF 03882845 and Placebo
• Placebo Comparator: Cohort 2
  
  Cohort 2 not studied
  Intervention: Drug: PF 03882845 and Placebo
• Placebo Comparator: Cohort 3
  
  Cohort 3 not studied
  Intervention: Drug: PF 03882845 and Placebo
• Placebo Comparator: Cohort 4
  
  Cohort 4 not studied
  Intervention: Drug: PF 03882845 and Placebo

Inclusion Criteria:

• Healthy male and female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests.
• An informed consent document signed and dated by the subject or a legally acceptable representative.
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• Evidence or history of clinically significant disease, allergy or clinical findings at screening.
• A positive urine drug screen, history of significant regular alcohol consumption within 6 months of screening or use of tobacco or nicotine containing products within the three months preceding study date or a positive urine cotinine at screening or Day -3.
• Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing.
• Pregnant or nursing females; females of childbearing potential.